miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes by Qian, Li et al.
Article
The Rockefeller University Press  $30.00
J. Exp. Med. Vol. 208 No. 3  549-560
www.jem.org/cgi/doi/10.1084/jem.20101547
549
Myocardial  infarction  (MI),  caused  by  acute 
occlusion of the coronary artery, is one of the 
leading causes of death and disability world-
wide  (Mackman,  2008).  Over  seven  million 
people die each year from acute MI or progres-
sive cardiac dysfunction after coronary artery 
occlusion. MI induces cardiac cell death and 
ischemic stress in surviving myocytes bordering 
the region of infarct (border zone [BZ]), which 
triggers left ventricle (LV) remodeling, leading to 
dilation, hypertrophy, and fibrosis (Swynghedauw, 
1999).  Scar  formation  and  pathological  LV   
remodeling result in cardiac dysfunction and 
eventually lead to heart failure (Swynghedauw, 
1999). Apoptosis (programmed cell death) con-
tributes significantly to cardiomyocyte loss dur-
ing acute MI, particularly in the BZ, and during 
subsequent remodeling events (Kang et al., 2000; 
Kitsis et al., 2007). Because cardiomyocytes are 
terminally differentiated and have little potential 
for division, controlling the loss of cardiomyocytes 
after injury holds potential therapeutic value.
Posttranscriptional  regulation  involving  a 
class  of  small  noncoding  RNAs  known  as   
microRNAs  (miRNAs; Ambros,  2003;  Zhao 
and  Srivastava,  2007;  Ruvkun,  2008;  Bartel, 
2009) has emerged as a major regulator of 
numerous cellular processes, including those   
involved  in  the  heart.  Through  imperfect   
sequence-specific binding to their messenger 
RNA  (mRNA)  targets,  miRNAs  negatively 
influence the expression of proteins by destabi-
lizing target mRNAs or inhibiting translation 
(Ambros, 2003; Zhao et al., 2005; Zhao and 
Srivastava, 2007; Ruvkun, 2008; Bartel, 2009). 
miRNAs control various aspects of heart de-
velopment and function, including cell prolif-
eration (Zhao et al., 2005, 2007; Chen et al., 
2006), lineage differentiation (Kwon et al., 2005; 
Sokol  and Ambros,  2005;  Chen  et  al.,  2006; 
Ivey et al., 2008), and cardiac conduction (Yang 
et al., 2007; Zhao et al., 2007). Several miRNAs 
are  dysregulated  during  cardiac  remodeling 
after injury or stress (van Rooij et al., 2006, 
2007,  2008;  Carè  et  al.,  2007),  including   
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Acute myocardial infarction (MI) involves necrotic and apoptotic loss of cardiomyocytes. 
One strategy to salvage ischemic cardiomyocytes is to modulate gene expression to pro-
mote cell survival without disturbing normal cardiac function. MicroRNAs (miRNAs) have 
emerged as powerful regulators of multiple cellular processes, including apoptosis, suggest-
ing that regulation of miRNA function could serve a cardioprotective function. In this 
study, we report that miR-24 (miRNA-24) expression is down-regulated in the ischemic 
border zone of the murine left ventricle after MI. miR-24 suppresses cardiomyocyte apop-
tosis, in part by direct repression of the BH3-only domain–containing protein Bim, which 
positively regulates apoptosis. In vivo expression of miR-24 in a mouse MI model inhibited 
cardiomyocyte apoptosis, attenuated infarct size, and reduced cardiac dysfunction. This 
antiapoptotic effect on cardiomyocytes in vivo was partially mediated by Bim. Our results 
suggest that manipulating miRNA levels during stress-induced apoptosis may be a novel 
therapeutic strategy for cardiac disease.
© 2011 Qian et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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after overexpression or inhibition of miR-24, we found that 
miR-24 negatively regulated this marker of apoptosis (Fig. 1,   
F–I). Quantification for activated Caspase 3–positive cardio-
myocytes further confirmed the results (Fig. 1, J and K). Cell 
cycle patterns were similar among miR-24 mimic– and miR-24 
inhibitor–expressing and control cells (Fig. S3, E and F).
miR-24 directly targets Bim for repression  
in cardiomyocytes
Because  miR-24  inhibited  cardiomyocyte  apoptosis,  we 
searched for direct downstream effectors/targets by which 
miR-24 exerts its function. We used established computa-
tional algorithms to predict potential miR-24 target genes 
(Krek et al., 2005; Rajewsky, 2006; Bartel, 2009) and performed 
gene expression analyses. Among down-regulated genes, the 
proapoptotic Bcl2 family protein Bim was a strong candidate 
target based on the presence of predicted miR-24 binding 
sites. Bim mediates mitochondrial and ER stress–induced apop-
tosis, and its levels are controlled by multiple mechanisms, in-
cluding transcriptional and posttranscriptional events such as 
phosphorylation,  ubiquitination,  proteasomal  degradation, 
and miRNA regulation (i.e., miR-17-92; Dijkers et al., 2000; 
Puthalakath and Strasser, 2002; Ley et al., 2005; Puthalakath   
et al., 2007; Ventura et al., 2008; Xiao et al., 2008).
To test whether Bim is also regulated by miR-24, qPCR 
and Western blots of cardiomyocytes transfected with miR-24 
mimic or inhibitor were performed. mRNA and protein 
levels of Bim were down-regulated when miR-24 was over-
expressed, whereas inhibiting miR-24 function resulted in 
up-regulation of Bim (Fig. 2, A and B). We identified two 
conserved miR-24 binding sites in the Bim mRNA 3 un-
translated region (UTR; Fig. 2 C). To test whether miR-24 
repressed Bim by binding to these sites, the Bim 3 UTR   
was inserted into the 3 UTR of a luciferase reporter, down-
stream of the coding region. The constitutively active reporter 
was cotransfected with miR-24 mimic, inhibitor, or miR-
24  cloned  in  an  expression  vector  (pEF–miR-24)  into 
HeLa cells. Transfection of the Bim 3 UTR chimeric lucifer-
ase reporters with miR-24 (miR-24 mimic or pEF–miR-24) 
resulted in a decrease in luciferase activity, whereas co-
transfection with miR-24 inhibitor resulted in increased lu-
ciferase activity (Fig. 2 C). Mutations of the miR-24 binding 
sites in the Bim 3 UTR abolished miR-24 responsiveness 
(Fig. 2 C), suggesting that miR-24 represses Bim by physically 
binding to its 3 UTR. The same luciferase experiment was 
performed in cardiomyocytes, confirming the results from 
HeLa cells (Fig. S3 G).
We investigated whether miR-24 repression of Bim in 
primary cardiomyocytes could account for some of the effects 
of miR-24 on the apoptotic pathway. Bim knockdown led to 
a reduction in the number of apoptotic cells (Fig. 2 D and not 
depicted),  phenocopying  overexpression  of  miR-24.  Most 
importantly, the increase in apoptotic cell number caused by 
inhibition of miR-24 could be reversed by knockdown of 
Bim (Fig. 2 E and not depicted), suggesting an epistatic rela-
tionship between miR-24 and Bim.
miR-29 (miRNA-29) and miR-21 (Thum et al., 2008;   
van Rooij et al., 2008; Dong et al., 2009).
In  this  study,  we  identify  miR-24  as  an  antiapoptotic 
miRNA that is down-regulated in the ischemic zones of the 
LV after acute MI. We show that miR-24 directly targets the 
proapoptotic protein Bim within cardiomyocytes for repres-
sion and inhibits apoptosis in vitro and in vivo. In vivo delivery 
of miR-24 after MI reduced scar size and improved long-term 
cardiac function.
RESULTS
miR-24 suppresses apoptosis
In an effort to identify miRNAs dysregulated within hours 
after MI, we found that miR-24 was highly down-regulated 
in the ischemic BZ but not in the nonischemic distant zone 
(DZ) of the LV 24 h after MI (Fig. 1, A–C). miR-23a and 
miR-23b, encoded by the same cluster as miR-24, were also 
down-regulated at the BZ but to a lesser extent; in contrast, 
expression of miR-27a and miR-27b, which are also clus-
tered with miR-24, was not altered at the BZ (Fig. S1 A). 
miR-24 expression was normally enriched in the adult mouse 
heart, specifically in sorted cardiac myocyte and fibroblast 
populations but not in endothelial cells (Fig. S1, B–H). Inter-
estingly, miR-24 down-regulation was attenuated over time, 
and its expression was restored back to wild-type levels by   
4 wk after MI (Fig. 1, A and B). We quantified apoptotic car-
diomyocytes in the BZ and DZ regions over time (Fig. 1,   
D and E) and found a close correlation between down-
regulation of miR-24 and increase in apoptosis (Fig. 1, A–E).
To investigate miR-24 function, we transfected primary 
cardiomyocytes with chemically synthesized double-stranded 
oligonucleotides that mimic the function of endogenous ma-
ture miR-24 (miR-24 mimic) or modified antisense oligori-
bonucleotides that inhibit miR-24 function (miR-24 inhibitor). 
Transfection efficiency (80%) was monitored by FACS 
analysis of cotransfected Alexa Fluor 488–conjugated oligo-
nucleotides (Fig. S2, A and B), expression levels were evalu-
ated by real-time quantitative PCR (qPCR; Fig. S2, C and D), 
and  functional  activity  of  transfected  miR-24  oligonucle-
otides was measured by luciferase sensor experiments (Fig. S2 E). 
Additional miR-24 mimic and inhibitor controls in which 
the seed sequence of miR-24 was mutated were used (see 
Materials and methods).
miR-24 expression in cardiomyocytes increased cell num-
ber by 53%, and inhibition of miR-24 function decreased cell 
number by 45% 48 h after transfection. We did not observe a 
difference in cell number upon introduction of control mimic, 
control inhibitor, or mock transfection (Lipofectamine only). 
However, the number of live cells (propidium iodide [PI]) 
positive for AnnexinV, an early apoptosis marker, was in-
creased  when  miR-24  was  inhibited.  Conversely,  fewer 
AnnexinV+PI cells were seen when miR-24 was overex-
pressed (Fig. S3, A–D). During later apoptosis, DNA fragmen-
tation results from activation of endonucleases (Hengartner, 
2000). Using TUNEL (Tdt-mediated dUTP-biotin nick end 
labeling) staining to detect fragmented DNA in cardiomyocytes JEM VOL. 208, March 14, 2011 
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Figure 1.  miR-24 is down-regulated early after MI and inhibits apoptosis. (A and B) qPCR of miR-24 was performed on RNA extracted 
from the BZ and DZ of hearts 24 h, 3 d, and 1 and 4 wk after coronary artery ligation (MI) or sham surgery. (C) In situ hybridization using miR-24 
locked nucleic acid (LNA) probe on heart sections from MI and sham operated mice 24 h after surgery. (D) TUNEL staining of infarcted hearts 24 h 
after coronary artery ligation. Cardiomyocytes were costained with antibody to -Actinin. DAPI was used for nuclear staining. (E) Percentage of 
TUNEL-positive cardiomyocytes (CM) at BZ of hearts over time after MI. n = 3 for each time point. (F and G) TUNEL and -Actinin staining on pri-
mary cardiomyocytes transfected with mimic control, miR-24 mimic, or miR-24mut mimic (F) or transfected with inhibitor control, miR-24 inhibi-
tor, or miR-24mut inhibitor (G). (H and I) Quantification of percentage of TUNEL-positive cardiomyocytes in F and G. (J and K) Quantification of 
percentage of Caspase 3–positive cardiomyocytes. All experiments were repeated three times (technical triplicates) with biological triplicates  
(n = 3). Error bars indicate SEM (*, P < 0.05). Bars, 50 µm.552 miR-24 inhibits cardiomyocyte apoptosis | Qian et al.
Figure 2.  Bim is a direct target of miR-24. (A) qPCR of Bim mRNA from cardiomyocytes transfected with control (mock transfection with Lipo-
fectamine 2000 only), miR-24 mimic, or miR-24 inhibitor. (B) Western blot comparing protein levels of Bim in control (mock transfection) and miR-24 
mimic– or miR-24 inhibitor–expressing cells. Quantification compared with control (set as 1) is shown above the panel. (C) Conserved miR-24 binding 
sites in the Bim 3 UTR and relative luciferase activity (RLA) in HeLa cells expressing miR-24 mimic, miR-24 precursor (in expression vector, pEF–miR-24), 
or inhibitor compared with control. Base pairs highlighted in color (miR-24 in red and Bim 3 UTR in green) are seed sequences that are complimentary 
between miRNA and target. Mutations in miR-24 binding sites for luciferase assay in 3 UTR are indicated. Controls are set up as 1, indicated by the 
dashed line. (D) Primary cardiomyocytes (CM) expressing control siRNA or Bim siRNA were stained with AnnexinV, PI, TUNEL, or activated Caspase 3. Dot 
plots show representative staining by flow cytometry, and arrows indicate the quadrant of AnnexinV+PI apoptotic cells. (E) Primary cardiomyocytes co-
transfected with Bim siRNA and miR-24 inhibitor or control inhibitor were stained with AnnexinV, PI, TUNEL, or activated Caspase 3. Dot plots show rep-
resentative staining by flow cytometry, and arrows indicate the quadrant of AnnexinV+PI apoptotic cells. All experiments were repeated three times 
(technical triplicates) with biological triplicates (n = 3). Bar graphs show mean ± SEM (*, P < 0.05).JEM VOL. 208, March 14, 2011 
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mimic than in control mimic–treated mice (Fig. 3, A and B). 
This result was confirmed by using another apoptotic marker, 
activated Caspase 3, in combination with -Actinin (Fig. 3 C 
and not depicted). In parallel, we assayed for phosphorylated 
histone H3 (pH3) and -Actinin to compare the difference 
in the progression of cardiomyocyte mitosis among the two 
groups of mice. We detected no mitotic cardiomyocytes in 
either miR-24 mimic– or control mimic–treated mice (un-
published  data). To  determine  whether  the  inhibition  of 
apoptosis by miR-24 affected the degree of myocardial dam-
age, we performed Evans blue/triphenyltetrazolium chloride 
(TTC) double staining to assess the area at risk (AAR) and 
the infarct size of myocardium 24 h after coronary ligation. 
Treatment of miR-24 led to a decrease in infarct size but no 
change in AAR (Fig. 3, D and E), suggesting that miR-24 ex-
pression reduced cardiac damage shortly after MI.
In vivo delivery of miR-24 reduces cardiac dysfunction  
in a mouse MI model
Acute MI in mice causes myriad hemodynamic stresses, which 
trigger  left  ventricular  remodeling  and  eventually  lead  to 
functional decompensation and heart failure (Lutgens et al., 
1999; Bock-Marquette et al., 2004). We hypothesized that a 
In vivo delivery of miR-24 inhibits apoptosis  
in a mouse MI model
Apoptotic signals are propagated in response to ischemic stress 
in the heart. Thus, we speculated that the extensive apoptosis 
after MI may be enhanced by the decreased levels of miR-24. 
We  used  a  Lipofectamine-mediated  in  vivo  transfection 
method (Yang et al., 2007) to locally deliver miR-24 mimics 
to the infarcted hearts of mice in an effort to restore miR-24 
levels. To validate the delivery efficiency, fluorescently labeled 
oligonucleotides mixed with Lipofectamine were injected. By 
24 h after the procedure, strong fluorescence around the in-
jection area revealed efficient uptake (Fig. S4, A–C). qPCR 
and in situ hybridization of miR-24 revealed high expression 
levels in the injected areas (Fig. S4, D and E), although it is 
difficult to directly assess the functionality of injected oligo-
nucleotides in vivo.
To determine whether miR-24 mimic treatment could 
inhibit ischemia-induced apoptosis of cardiomyocytes in vivo, 
we  combined TUNEL  labeling  with  the  cardiomyocyte 
marker  -Actinin  on  infarcted  mouse  hearts  treated  with 
miR-24 or control mimics. The percentage of TUNEL-positive 
(apoptotic) cardiomyocytes in the BZs along the infarct area 
was 62% (P < 0.05) lower in animals treated with miR-24 
Figure 3.  In vivo delivery of miR-24 inhibits apoptosis. (A and B) Immunohistochemistry of control mimic– or miR-24 mimic–treated heart sections 
marking TUNEL-positive cardiomyocytes costained with -Actinin antibody within the BZ of infarcted hearts. Quantification is shown in B. (C) Quantifica-
tion for activated Caspase 3+ cardiomyocytes (CM) at BZ. (D) Representative pictures of Evans blue/TTC staining on four continuous slices of LV from rep-
resentative hearts of control mimic– or miR-24 mimic–injected mouse. (E) Blinded quantification of size of the AAR and infarct size as described in 
Materials and methods. All staining in this figure was performed on hearts 24 h after MI. Measurements were repeated three times (technical triplicates), 
with biological sample size indicated in each panel. The mean number from technical triplicates was used for statistical calculation. Error bars indicate 
SEM (*, P < 0.05). Bars: (A) 50 µm; (D) 500 µm.554 miR-24 inhibits cardiomyocyte apoptosis | Qian et al.
controls (Fig. 4 A). Moreover, cardiac output (the product of 
SV and heart rate) was increased in the miR-24 recipients 
(Fig. 4 A). This was attributable to better structure and con-
tractility of the LV because heart rate was unaltered (Fig. S5 A). 
To monitor cardiac structure and function at several time 
decrease in cardiac cell death by miR-24 would translate into 
improved heart function. Therefore, we assessed cardiac func-
tion 12 wk after MI by using magnetic resonance imaging 
(MRI). MRI revealed that the miR-24–treated mice had a 
higher ejection fraction (EF) and stroke volume (SV) than 
Figure 4.  In vivo delivery of miR-24 blunts effects of MI. After MI, miR-24 or control mimic was injected along the BZ of infarct. (A) EF, SV, and 
cardiac output (CO) of the LV were measured by MRI 12 wk after MI. (B) M-mode echocardiography of representative hearts 3 d after MI. (C) Fractional 
shortening (FS), EF, and cardiac output at varying time points were measured using high-resolution echocardiography. Data were collected 1 d before and 
3 d, 4 wk, and 12 wk after MI in a blinded fashion. (D) qPCR of ANF and BNP on RNA extracted from BZ of MI hearts 24 h after injection of control or 
miR-24 mimic. (E) Stress-responsive miRNAs were measured by qPCR 24 h after MI. Data in D and E are shown relative to control, indicated by dashed 
lines. (F and G) Azan staining was performed on heart sections 4 wk after MI with miR-24 or control mimic injected. RV, right ventricle. Bars, 500 µm.  
(H and I) Quantification of scar size was calculated by measurement of both scar area (H) and scar circumference (I). (J) Western blots for activated Cas-
pase 3, Caspase 12, activated Caspase 12, Caspase 9, Bim, and GAPDH in protein extracts from control mimic– or miR-24 mimic–injected hearts 24 h after 
MI, as well as hearts without MI (sham). Relative quantification of Western blots is shown to the right of each panel; comparison was made between 
control mimic (set as 1) and miR-24 mimic after MI. The vertical black line indicates that intervening lanes have been spliced out. For all histograms, sam-
ple size (n) is indicated for each group. Each experiment was repeated three times (technical triplicates), and the mean number was used for statistical 
analyses. Error bars indicate SEM (*, P < 0.05; **, P < 0.01).JEM VOL. 208, March 14, 2011 
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in less apoptosis at both the IZ and BZ of MI hearts 24 h after 
MI, as measured by TUNEL and activated Caspase 3 staining 
(Fig. 5, A and B; and not depicted).
To  further  investigate  the  relationship  of  miR-24  and 
Bim, we performed loss of function experiments of miR-24 
by inhibiting endogenous miR-24 levels with Lipofectamine-
mediated in vivo transfection of a miR-24 inhibitor, as de-
scribed previously (Yang et al., 2007), with or without Bim 
knockdown. The  miR-24  knockdown  was  confirmed  by 
qPCR (Fig. S4 G). Inhibition of miR-24 resulted in increased 
apoptosis in BZ cardiomyocytes, increased expression of the 
downstream target Bim, and increased activity of Caspase 3, 
Caspase 12, and Caspase 9 (Fig. 5, C–E; and not depicted). 
Co-delivery of Bim siRNA and miR-24 inhibitor partially 
rescued the proapoptotic effects of miR-24 inhibition (Fig. 5, 
F and G; and not depicted).
DISCUSSION
In this study, we reveal a novel role for miR-24 in the regula-
tion of mammalian cardiomyocyte apoptosis. We found that 
miR-24 inhibits apoptosis in cardiomyocytes in vitro and   
in vivo using a mouse MI model. In addition, we identified Bim 
as one of the direct targets of miR-24 and, through epistasis 
analyses, found that Bim mediates a part of miR-24’s effect 
on apoptosis. Finally, introduction of miR-24 in vivo did not 
disturb the normal function of the heart but partially pro-
tected the heart from injury. The beneficial effects of miR-24 
in MI hearts, while statistically significant by our measure-
ment, are quite small and may be below the true sensitivity of 
the techniques being used. Future experimentation using more 
robust and accurate assays with a large sample number is 
needed for validation of applying this miRNA in treating 
ischemic cardiac disease. In addition, the improvement in 
heart function and reduction in scar size by overexpressing 
miR-24 might be caused by other functions of miR-24 inde-
pendent of apoptosis or a combination of all. Further cardiac 
function analyses and scar size measurements when inhibiting 
the antiapoptotic function of miR-24 (i.e., knocking down 
the downstream components in miR-24–mediated apoptosis 
pathway) will hopefully provide some clues.
Like most miRNAs, miR-24 functions in many other bi-
ological processes and pathways. miR-24 was first reported to 
negatively regulate erythroid differentiation through inhibi-
tion of human activin type I receptor ALK4 (Wang et al., 
2008). In addition, miR-24 appears to affect the tumor sup-
pressor p16 (Lal et al., 2008), the DNA repair process, and cell 
cycle regulation (Lal et al., 2009a,b; Rogler et al., 2009). Par-
ticularly relevant to this study, miR-24 is required to prevent 
apoptosis during normal development of the retina in frogs 
(Walker and Harland, 2009), suggesting evolutionary conser-
vation of miR-24 function, although the mechanisms may 
be divergent. These findings support the idea that a single 
miRNA,  like  miR-24,  can  regulate  multiple  independent 
pathways that may converge on a common biological out-
come such as regulation of apoptosis. Other miRNAs, such 
as miR-21, may also play a role in regulating the cardiac 
points after MI, we used high-resolution echocardiography 
(Fig. 4, B and C; and Fig. S5, B and C). miR-24– and control-
treated mice underwent serial imaging 1 d before and 3 d,   
4 wk, and 12 wk after MI. All mice showed a reduction in left 
ventricular function after coronary artery ligation, confirm-
ing successful induction of MI (Fig. 4, B and C; and Fig. S5 B). 
However, in mice treated with miR-24, the initial loss of 
contractility was significantly attenuated compared with con-
trols (Fig. 4, B and C; and Fig. S5 B).
As a molecular readout of cardiac dysfunction, we per-
formed qPCR to monitor the expression levels of atrial natri-
uretic factor (ANF) and brain natriuretic peptide (BNP) from 
miR-24–injected and control hearts. Both ANF and BNP 
were up-regulated 24 h after MI in controls as expected 
(Fig. 4 D). The up-regulation of ANF and BNP was attenuated 
by injection of miR-24 mimic in infarcted hearts (Fig. 4 D). We 
also assessed the expression level of a battery of stress-responsive 
miRNAs by qPCR. miR-29, miR-195, and miR-208 levels, 
which are dramatically reduced upon MI (van Rooij et al., 
2006, 2007, 2008), were partially restored by overexpression 
of miR-24 (Fig. 4 E).
Consistent with the improvement of cardiac function, in-
jection of miR-24 resulted in a smaller scar size 4 wk after MI 
(Fig. 4, F–I; and Fig. S5, D–F). Mice treated with miR-24 had 
a 33% reduction in scar circumference and a 46% reduction 
in scar area (P < 0.05; Fig. 4, F–I; and Fig. S5, D–F). Because 
stimulation of neovascularization could be another mecha-
nism by which miR-24 decreased infarct size and improved 
cardiac function (van Laake et al., 2006), we quantified vascu-
lar density in the infarcted area, BZ, and distant myocardium. 
We found no difference in vessel formation between miR-24– 
and control-injected hearts (unpublished data).
miR-24 modulates apoptosis and suppresses Bim in vivo
Because our cell culture experiments (Figs. 1 and 2) demon-
strated that miR-24 inhibited apoptosis and targeted the pro-
apoptotic Bcl2 family protein Bim, we tested whether miR-24 
regulated the same apoptosis pathway in vivo. Protein was ex-
tracted from the infarct zone (IZ) and BZ of mouse hearts   
24 h after coronary ligation and injection with miR-24 mimic 
or control mimic. Consistent with its inhibitory role in apop-
tosis, miR-24 led to reduced protein levels of the final effec-
tor Caspase, activated Caspase 3, compared with controls after 
MI (Fig. 4 J). Caspase 8 was not significantly affected by 
miR-24 expression (not depicted); however, the increases in 
Caspase 12 and Caspase 9 were significantly attenuated in in-
farcted mouse hearts treated with miR-24 (Fig. 4 J). In addi-
tion,  the  increase  in  protein  level  of  Bim  after  MI  was 
dampened in these hearts compared with controls (Fig. 4 J).
Next we determined whether a decrease in Bim could 
mimic the in vivo effect of miR-24 expression on cardio-
myocyte apoptosis. We delivered Bim small interfering RNA 
(siRNA) cocktails to the IZ and BZ of mouse hearts after 
coronary artery ligation. RNA and protein levels of Bim were 
measured  to  ensure  efficient  knockdown  of  Bim  (Fig.  S5,   
G and H). We found that inhibition of Bim expression resulted 556 miR-24 inhibits cardiomyocyte apoptosis | Qian et al.
Figure 5.  In vivo inhibition of Bim reduces miR-24 inhibitor–induced apoptosis. (A and B) After MI, control or Bim siRNA was injected along the 
BZ of infarct. Immunohistochemistry of heart sections labeling TUNEL-positive cardiomyocytes, marked by -Actinin antibody within the BZ. DAPI indi-
cates nuclei. Quantification of TUNEL+ or activated Caspase 3+ cells is shown in B. (C and D) Cardiomyocyte (CM) apoptosis was determined by TUNEL and 
activated Caspase 3 stainings on heart sections at the BZ of infarcted hearts with miR-24 or control inhibitor injected. (E) Western blots for activated 
Caspase 3, Caspase 12, activated Caspase 12, Caspase 9, Bim, and GAPDH in protein extracts from control inhibitor– or miR-24 inhibitor–injected hearts 
24 h after MI, as well as hearts without MI (sham). Relative quantification of Western blots is shown to the right of each panel; comparison was made JEM VOL. 208, March 14, 2011 
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5-CCCTGCAGTGGGAACGAAGACA  GCTGATTTATAAGGC-3  and 
5-GCCTTATAAATCAGCTGTCTTCGTTCCCACTGCAGGG-3;  
and  5-GTTTCACTCGTCAACGAAGACAAATGTCTCTGTGC-3  and 
5-GCACAGAGACATTTGTCTTCGTTGACGAGTGAAAC-3  (the  un-
derlined nucleotides are mutated ones).
Quantitative  real-time  PCR.  RNA  was  extracted  by  the TRIZOL 
method (Invitrogen). RT-PCR was performed using the Superscript III first-
strand synthesis system (Invitrogen). qPCR was performed using the ABI 
7900HT (TaqMan; Applied Biosystems) per the manufacturer’s protocols. 
Optimized primers from TaqMan Gene Expression Array were used. miRNA 
RT was conducted using the TaqMan MicroRNA Reverse Transcription kit 
(Applied Biosystems). miRNA real-time PCR (quantitative RT-PCR) was 
performed per the manufacturer’s protocols by using primers from TaqMan 
MicroRNA assays (Applied Biosystems). Expression levels were normalized 
to Gapdh expression and RNU6 (miRNA qPCR).
Cell culture, transfection, and luciferase assay. Primary cardiomyocytes 
from mouse neonatal hearts were isolated and maintained as described previ-
ously (Ieda et al., 2009). Lipofectamine 2000 (Invitrogen)–mediated transfec-
tion  was  performed  according  to  Invitrogen’s  protocol.  miR-24  mimic   
(5-UGGCUCAGUUCAGCAGGAACAG-3), mimic control (5-UUCU-
CCGAACGUGUCACGUTT-3), miR24mut mimic (5-UGGCUCAGU-
UCAGUAAGAACCG-3), miR-24 inhibitor (5-ACCGAGUCAAGUCG-
UCCUUGUC-3),  inhibitor  control  (5-UCUACUCUUUCUAGGAG-
GUUGUGA-3), and miR24mut inhibitor (5-ACCGAGUCAAGUCAU-
UCUUGGC-3; the underlined nucleotides are mutated ones) were purchased 
from Thermo Fisher Scientific and Shanghai GenePharma Co. For each 
transfection in 1 well of a 6-well plate, 40 pmol of mimic or inhibitor was 
used. For plasmid transfection, 100 ng of plasmid was transfected in 1 well of 
a 6-well plate. Luciferase assays were performed as described previously (Zhao   
et al., 2005) with the Dual-Luciferase reporter assay system (Promega).
Western  blots  and  immunocytochemistry. Western  blots  were  per-
formed as described previously (Zhao et al., 2005). Mouse monoclonal anti–
Caspase 8 (Sigma-Aldrich), mouse monoclonal anti–Caspase 9 (Sigma-Aldrich), 
rabbit  anti–Caspase  3  (Sigma-Aldrich),  rat  monoclonal  anti–Caspase  12 
(Sigma-Aldrich), and rabbit polyclonal antibody against Bim (aa 4–195 of 
BimEL form) were all used at a 1:1,000 dilution for Western blots. All Western 
blots were quantified using AlphaImager software (Alpha Innovations). Im-
munocytochemistry  was  performed  according  to  a  standard  protocol.  In 
brief, cells were fixed in 10% formalin (vol/vol) for 15 min on ice and washed 
with PBS twice. Cells were then incubated with primary antibody for 1 h at 
room temperature and washed with PBS three times and then incubated 
with  secondary  antibody  for  0.5  h. After  washing  with  PBS,  cells  were 
mounted in Vectashield with DAPI (Vector Laboratories). Mouse anti–- 
Actinin was used at 1:400; guinea pig anti-Vimentin (Progen) was used at 
1:200; rabbit anti–Caspase 3 (Sigma-Aldrich) was used at 1:200 for immuno-
cytochemistry. Alexa Fluor 546 or Alexa Fluor 488 anti–mouse (Invitrogen) 
was used at 1:200 as secondary antibody. TUNEL staining was performed   
using the In Situ Cell Death Detection kit, Fluorescein (Roche) per the 
manufacturer’s protocol.
Flow  cytometry.  For  FACS  analysis  to  detect  early  apoptotic  cells 
(AnnexinV+PI), 5 × 105 dissociated cells were washed twice in PBS and resus-
pended in 1× binding buffer (BD). Then the cells were stained with 1 µl 
AnnexinV-FITC and 0.5 µl PI (BD) for 30 min in the dark and followed 
by FACS analysis with FACSCalibur (BD). For FACS analysis of cell cycle, dis-
sociated cells were fixed and permeabilized by cold 70% ethanol (overnight 
response  to  ischemic  injury  (Thum  et  al.,  2008;  Dong   
et al., 2009).
miR-24 is expressed in both cardiomyocytes and fibro-
blasts. Our experiments demonstrate that miR-24 can exert 
antiapoptotic effects in cardiomyocytes in a cell-autonomous 
fashion. We and others have shown that cardiac fibroblasts can 
function as major signaling centers to affect the neighboring 
cardiomyocytes (Ieda et al., 2009; Takeda et al., 2010), and it is 
quite possible that miR-24 also functions in cardiac fibroblasts 
to promote cardiomyocyte survival. In this case, miR-24 would 
likely regulate pathways leading to paracrine secretion of sur-
vival factors that impinge on neighboring myocytes. Future 
studies of fibroblast-specific expression of miR-24 could help 
resolve this issue.
It is curious that an miRNA that represses an apoptotic 
factor such as Bim in the setting of ischemia would be down-
regulated. One might expect that such an miRNA would be 
up-regulated to protect the cells from ischemic damage, par-
ticularly in the BZ which is attempting to survive in hypoxic 
conditions. However, the down-regulation may reflect the 
need to remove cells that are under ischemic stress. It will be 
interesting to determine whether the ischemia-induced miR-24 
down-regulation has other more beneficial consequences 
through yet unknown targets.
The finding that miR-24 targets the Bcl2 family member 
Bim for repression highlights an important facet of miRNA-
mediated regulation of critical cellular events. The dosage of Bim 
is apparently very important, as cells have engineered numer-
ous mechanisms to quantitatively regulate its protein levels. 
Bim mediates both mitochondrial and ER stress–induced 
apoptosis and is regulated through multiple cellular modalities, 
including phosphorylation, ubiquitination, and proteosome-
mediated degradation (Dijkers et al., 2000; Puthalakath and 
Strasser, 2002; Ley et al., 2005; Puthalakath et al., 2007). Our 
findings reveal yet another layer of posttranscriptional Bim 
regulation involving miR-24 and suggest that the cell uses 
numerous back-up mechanisms and regulatory pathways to 
carefully titrate the dose of this central regulator of apoptosis.
MATERIALS AND METHODS
Plasmid construction. Bim 3 UTR was cloned from mouse genomic DNA 
and cardiomyocyte cDNA (Fig. S3 H) with the primers 5-AGCGCTCTG-
CACTGTGTCGATGTGAACGG-3  and  5-ATGGCAGGGCTGTCA-
GGGATAGGGATGTC-3. Amplified DNA was cloned into pCRII vector 
and subsequently cloned into pMIR-REPORT vector (Applied Biosystems). To 
express miR-24 in HeLa cells for luciferase assay, the genomic sequence contain-
ing premiR-24-2 plus flanking sequence (total 300 bp) were inserted into 
pEF-DEST51 (Invitrogen) with the primers 5-CACCATCTCCTCAGGCC-
GCTGCTG-3 and 5-CTATCTGCTTTGGGGAACCACAG-3. Site- 
directed PCR-mediated mutagenesis was performed using the QuikChange II 
XL Site-Directed Mutagenesis kit (Agilent Technologies). The following two 
pairs of primers were used to mutate both miR-24 binding sites in Bim 3 UTR: 
between control inhibitor (set as 1) and miR-24 inhibitor after MI. The vertical black line indicates that intervening lanes have been spliced out. (F) TUNEL 
stainings on MI heart sections coinjected with Bim siRNA or control siRNA and miR-24 inhibitor. (G) Quantification of TUNEL+ or activated Caspase 3+ 
cardiomyocytes. All experiments were repeated three times (technical triplicates), with biological duplicates indicated in each panel. Error bars indicate 
SEM (*, P < 0.05; **, P < 0.01). All data in this figure were collected 24 h after MI. Bars, 50 µm.
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oxygen administered via an MRI-compatible mobile inhalation anesthesia 
system (VetEquip) and maintained at 37°C. Two electrocardiography (ECG) 
leads were inserted into the right front and left rear leg. ECG waveforms 
were monitored with a small animal monitoring and gating system (SA In-
struments). The mouse was then placed into a homemade 1H birdcage coil 
with an inner diameter of 32 mm. A group of ECG (R-wave rising edge)-
triggered spin echo scout images were acquired first to define the oblique 
plane of the short axis. Then an ECG-triggered two-dimensional gradient 
echo sequence with an echo time of 2.75 ms, repetition time of 200 ms, and 
a flip angle of 45° was used to obtain cine short-axis images at 12 or 13 
phases per cardiac cycle. Each scan consisted of eight to nine contiguous 
slices spanning LV from apex to base with 1-mm thickness, a matrix size of 
128 × 128, a field of view of 25.6 × 25.6 mm, and four means.
Immunohistochemistry on mouse hearts. After perfusion fix, the heart 
was removed and fixed by immersion in 4% PFA in PBS (diluted from 20% 
PFA stock; Electron Microscopy Sciences) and routinely processed and paraf-
fin embedded. 5-µm sections were stained with hematoxylin and eosin and 
analyzed for regular morphology. To measure the infarct size at 4 wk after MI, 
LVs were cut from apex to base; sections from four equally distributed levels 
were Azan or Masson’s trichrome stained. Scar size was calculated as the per-
centage of the LV circumference, or total scar area divided by total LV area, 
and was summed from four transverse sections per heart. Adjacent sections 
were used to quantify vascular density after staining with PECAM-1 anti-
body (rat; 1:20; BD) as described previously (van Laake et al., 2006). To quan-
tify apoptotic cardiomyocytes, mouse hearts were removed 24 h after 
coronary artery ligation, fixed with 0.5% PFA in 5% sucrose, and routinely 
frozen embedded in OCT and processed for sectioning and staining with 
Caspase 3 (1:200) or TUNEL and -Actinin (mouse; 1:800; Sigma-Aldrich) 
as described previously (van Laake et al., 2008). TUNEL was performed using 
an In Situ Cell Death Detection kit, Fluorescein (Roche) per the manufac-
turer’s protocol. DAPI was used for nuclear counterstaining. Frozen heart 
sections were also stained with pH3 (rabbit; 1:100; Millipore), -Actinin, and 
DAPI to quantify proliferating cardiomyocytes.
Statistics. For echocardiography, MRI, TUNEL, Azan, Masson’s trichrome, 
Evans blue/TTC, and PECAM-1 staining quantification, statistical analysis 
was performed using SPSS version 15. Comparisons between groups were 
made by one-way analysis of variance or Mann–Whitney U test, as applica-
ble. Sample numbers were indicated in corresponding figures. For quantita-
tive RT-PCR, FACS, and luciferase assay, we used biological triplicates and 
technical triplicates; data were analyzed by unpaired Student’s t test. Error 
bars indicate SEM. *, P < 0.05; **, P < 0.01.
Online supplemental material. Fig. S1 shows qPCR for miR-23 and 
miR-27 in MI heart and the expression pattern of miR-24. Fig. S2 shows 
validation for miR-24 mimic and inhibitor transfection in primary cardio-
myocytes. Fig. S3 shows that miR-24 regulates apoptosis but not cell cycle 
and miR-24 regulates Bim in cardiomyocytes. Fig. S4 shows validation for 
miR-24 mimic and inhibitor in vivo transfection. Fig. S5 shows additional 
MRI and echo data, Masson’s trichrome staining on hearts 4 wk after MI, 
and validation for Bim siRNA knockdown. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20101547/DC1.
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at 4°C). Subsequently, 10 µl of 500 µg/ml RNase and 10 µl of 1 mg/ml PI 
were added to resuspended cells and incubated at 37°C for 30 min in the 
dark. After washing with PBS twice, stained cells were analyzed by FACS-
Calibur. For FACS sorting of endothelial cells, dissociated cells from mouse 
hearts were stained with FITC rat anti–mouse CD31 (BD) for 30 min at 
room temperature. After washing with PBS twice, stained cells were sorted 
by Aria (BD).
Mouse MI model. The protocol was approved by institutional guidelines 
(University of California, San Francisco Institutional Animal Care and Use 
Committee). All  surgeries  and  subsequent  analyses  were  performed  in  a 
blinded fashion for genotype and intervention. Mice were anesthetized with 
2.4% isoflurane/97.6% oxygen and placed in a supine position on a heating 
pad (37°C). Animals were intubated with a 19-gauge stump needle and ven-
tilated with room air with a MiniVent Type 845 mouse ventilator (Hugo 
Sachs Elektronik-Harvard Apparatus; SV, 250 µl; respiratory rate, 120 breaths/
min). MI was induced by permanent ligation of the left anterior descending 
artery with a 7-0 Prolene suture as described previously (Bock-Marquette   
et al., 2004). Sham-operated animals served as surgical controls and were 
subjected to the same procedures as the experimental animals with the ex-
ception that the left anterior descending artery was not ligated. All surgical 
procedures were performed under aseptic conditions. 4 wk or 24 h after oc-
clusion,  the  heart  was  removed  for  perfusion  fix  (4%  paraformaldehyde 
[PFA]; paraffin sections for structural analysis and immunohistochemistry) or 
immersion fix (0.5% PFA in 5% sucrose; cryo sections for immunofluores-
cent staining), or the tissues within the IZ, BZ, and nonischemic zone distal 
to the IZ (DZ) were dissected for RNA or protein isolation.
Determination of the AAR and myocardial infarct size. 24 h after 
coronary ligation, the mice were anesthetized and cannulated with tubing. 
2% Evans blue (Sigma-Aldrich) was perfused into the aorta; thus, all myocar-
dial tissue was stained blue except the AAR. The LV was isolated and cut into 
four 1-mm pieces with the first cut at the ligation level. LV slices were 
stained in 1.5% TTC for 30 min at 37°C and then fixed in 4% PFA overnight 
at 4°C. The area of infarction was demarcated as a white area, whereas viable 
myocardium was stained red. Photographs were taken for both sides of each 
section. The AAR and the infarct area were determined via planimetry by 
using the computer software ImagePro (Bio-Rad Laboratories). Infarct size 
was calculated as the percentage of MI compared with the AAR using a pre-
viously described methodology (Kurrelmeyer et al., 2000).
In vivo delivery of miR-24 mimic, inhibitor, and Bim siRNA. With 
the chest open, oligonucleotides stabilized with 2-O-methyl modification 
pretreated with 20 µl Lipofectamine 2000 were injected into the myocar-
dium through an insulin syringe with incorporated 29-gauge needle (BD) 
into the myocardium. The dosages used per mouse were 40 ng miR-24 
mimic, 40 ng control mimic, 80 ng miR-24 inhibitor, 80 ng inhibitor control 
(Shanghai GenePharma Co.), 3 nmol Bim siRNAs (a pool of three target-
specific 20–25 nt siRNAs; Santa Cruz Biotechnology, Inc.), or 3 nmol nega-
tive control siRNAs (Santa Cruz Biotechnology, Inc.). For each type of 
oligonucleotide, one injection with a full dosage was used along the bound-
ary between the IZ and BZ (based on the blanched infarct area) after coro-
nary artery occlusion. After injection, the chest was closed with sutures, and 
the mouse was allowed to recover with mouse ventilator and heating pad.
Echocardiography.  Echocardiography  was  performed  by  the Vevo  770 
High-Resolution Micro-Imaging System (VisualSonics) with a 15-MHz lin-
ear array ultrasound transducer. The LV was assessed in both parasternal long- 
and short-axis views at a frame rate of 120 Hz. End systole or end diastole 
was defined as the phase in which the smallest or largest area of LV, respec-
tively, was obtained. Left ventricular end systolic diameter and left ventricular 
end diastolic diameter were measured from the LV M-mode tracing with a 
sweep speed of 50 mm/s at the papillary muscle level.
MRI. MRI was performed on a small animal scanner (DirectDrive 7T;   
Varian). Each mouse was anesthetized by inhalation of 2% isoflurane/98% JEM VOL. 208, March 14, 2011 
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